TY - JOUR
T1 - Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter-defibrillators
T2 - A propensity-matched analysis from a multicenter European registry
AU - Gulletta, Simone
AU - Gasperetti, Alessio
AU - Schiavone, Marco
AU - Vogler, Julia
AU - Fastenrath, Fabian
AU - Breitenstein, Alexander
AU - Laredo, Mikael
AU - Palmisano, Pietro
AU - Mitacchione, Gianfranco
AU - Compagnucci, Paolo
AU - Kaiser, Lukas
AU - Hakmi, Samer
AU - Angeletti, Andrea
AU - De Bonis, Silvana
AU - Picarelli, Francesco
AU - Arosio, Roberto
AU - Casella, Michela
AU - Steffel, Jan
AU - Fierro, Nicolai
AU - Guarracini, Fabrizio
AU - Santini, Luca
AU - Pignalberi, Carlo
AU - Piro, Agostino
AU - Lavalle, Carlo
AU - Pisanò, Ennio
AU - Viecca, Maurizio
AU - Curnis, Antonio
AU - Badenco, Nicolas
AU - Ricciardi, Danilo
AU - Dello Russo, Antonio
AU - Tondo, Claudio
AU - Kuschyk, Jürgen
AU - Della Bella, Paolo
AU - Biffi, Mauro
AU - Forleo, Giovanni B.
AU - Tilz, Roland
N1 - Publisher Copyright:
© 2022 Heart Rhythm Society
PY - 2022/7
Y1 - 2022/7
N2 - Background: A few limited case series have shown that the subcutaneous implantable cardioverter-defibrillator (S-ICD) system is safe for teenagers and young adults, but a large-scale analysis currently is lacking. Objectives: The purpose of this study was to compare mid-term device-associated outcomes in a large real-world cohort of S-ICD patients, stratified by age at implantation. Methods: Two propensity-matched cohorts of teenagers + young adults (≤30 years old) and adults (>30 years old) were retrieved from the ELISIR Registry. The primary outcome was the comparison of inappropriate shock rate. Complications, freedom from sustained ventricular arrhythmias, and overall and cardiovascular mortality were deemed secondary outcomes. Results: Teenagers + young adults represented 11.0% of the entire cohort. Two propensity-matched groups of 161 patients each were used for the analysis. Median follow-up was 23.1 (13.2–40.5) months. In total, 15.2% patients experienced inappropriate shocks, and 9.3% device-related complications were observed, with no age-related differences in inappropriate shocks (16.1% vs 14.3%; P = .642) and complication rates (9.9% vs 8.7%; P = .701). At univariate analysis, young age was not associated with increased rates of inappropriate shocks (hazard ratio [HR] 1.204 [0.675–2.148]: P = .529). At multivariate analysis, use of the SMART Pass algorithm was associated with a strong reduction in inappropriate shocks (adjusted HR 0.292 [0.161–0.525]; P <.001), whereas arrhythmogenic right ventricular cardiomyopathy (ARVC) was associated with higher rates of inappropriate shocks (adjusted HR 2.380 [1.205–4.697]; P = .012). Conclusion: In a large multicenter registry of propensity-matched patients, use of the S-ICD in teenagers/young adults was safe and effective. The rates of inappropriate shocks and complications between cohorts were not significantly different. The only predictor of increased inappropriate shocks was a diagnosis of ARVC.
AB - Background: A few limited case series have shown that the subcutaneous implantable cardioverter-defibrillator (S-ICD) system is safe for teenagers and young adults, but a large-scale analysis currently is lacking. Objectives: The purpose of this study was to compare mid-term device-associated outcomes in a large real-world cohort of S-ICD patients, stratified by age at implantation. Methods: Two propensity-matched cohorts of teenagers + young adults (≤30 years old) and adults (>30 years old) were retrieved from the ELISIR Registry. The primary outcome was the comparison of inappropriate shock rate. Complications, freedom from sustained ventricular arrhythmias, and overall and cardiovascular mortality were deemed secondary outcomes. Results: Teenagers + young adults represented 11.0% of the entire cohort. Two propensity-matched groups of 161 patients each were used for the analysis. Median follow-up was 23.1 (13.2–40.5) months. In total, 15.2% patients experienced inappropriate shocks, and 9.3% device-related complications were observed, with no age-related differences in inappropriate shocks (16.1% vs 14.3%; P = .642) and complication rates (9.9% vs 8.7%; P = .701). At univariate analysis, young age was not associated with increased rates of inappropriate shocks (hazard ratio [HR] 1.204 [0.675–2.148]: P = .529). At multivariate analysis, use of the SMART Pass algorithm was associated with a strong reduction in inappropriate shocks (adjusted HR 0.292 [0.161–0.525]; P <.001), whereas arrhythmogenic right ventricular cardiomyopathy (ARVC) was associated with higher rates of inappropriate shocks (adjusted HR 2.380 [1.205–4.697]; P = .012). Conclusion: In a large multicenter registry of propensity-matched patients, use of the S-ICD in teenagers/young adults was safe and effective. The rates of inappropriate shocks and complications between cohorts were not significantly different. The only predictor of increased inappropriate shocks was a diagnosis of ARVC.
UR - http://www.scopus.com/inward/record.url?scp=85127629646&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2022.02.029
DO - 10.1016/j.hrthm.2022.02.029
M3 - Journal articles
C2 - 35257974
AN - SCOPUS:85127629646
SN - 1547-5271
VL - 19
SP - 1109
EP - 1115
JO - Heart Rhythm
JF - Heart Rhythm
IS - 7
ER -